Table 4 Comparison of immune marker expression in TNBC and MBC samples
Metaplastic breast carcinoma immune checkpoint markers | |||||
|---|---|---|---|---|---|
Outcome | Level | TNBC (n = 119) | MBC (n = 27) | Total | p value |
Age at initial diagnosis | Mean (SD) | 51.9 (11.8) | 57.8 (15.3) | 53.0 (12.7) | 0.0281 |
CD8+% in stroma ≥ 10 | No | 25 (21.0%) | 6 (22.2%) | 31 (21.2%) | 1.0000 |
Yes | 94 (79.0%) | 21 (77.8%) | 115 (78.8%) | 0.2451 | |
CD8+% in tumor ≥ 10 | No | 66 (55.5%) | 22 (81.5%) | 88 (60.3%) | 0.0158 |
Yes | 53 (44.5%) | 5 (18.5%) | 58 (39.7%) | — | |
CD163+% in tumor ≥ 10 | No | 64 (53.8%) | 14 (51.9%) | 78 (53.4%) | 1.0000 |
Yes | 55 (46.2%) | 13 (48.1%) | 68 (46.6%) | 0.0765 | |
CD163+% in stroma ≥ 10 | No | 24 (20.2%) | 1 (3.7%) | 25 (17.1%) | 0.0468 |
Yes | 95 (79.8%) | 26 (96.3%) | 121 (82.9%) | — | |
PD-L1% in tumor ≥ 1 | No | 107 (89.9%) | 19 (70.4%) | 126 (86.3%) | 0.0133 |
Yes | 12 (10.1%) | 8 (29.6%) | 20 (13.7%) | — | |
PD-L1% in stroma ≥ 1 | No | 32 (26.9%) | 11 (40.7%) | 43 (29.5%) | 0.1665 |
Yes | 87 (73.1%) | 16 (59.3%) | 103 (70.5%) | — | |
PD-L1% overall ≥ 1 | No | 32 (26.9%) | 12 (44.4%) | 44 (30.1%) | 0.1025 |
Yes | 87 (73.1%) | 15 (55.6%) | 102 (69.9%) | — | |